Alliance Pharma, Novartis sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine oxytocin/ergometrine from Novartis for $11.5 million. Alliance already had rights to the product in the U.K. und...